ConductScience.org, home

Library / Genes

TYR: tyrosinase

1 protein, 207 patents, 3 drugs, 1 trial, 3,260 NIH grants and 18,387 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolTYRHGNC
NametyrosinaseHGNC
NCBI Gene ID7299NCBI Gene
HGNC IDHGNC:12442HGNC
EnsemblENSG00000077498NCBI Gene
AliasesATN, CMM8, OCA1, OCA1A, OCAIA, SHEP3NCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P14679Tyrosinase5291Ensembl, GeneID, HGNCUniProt

Patents 207

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
EP 4824265 A12026-10-2115P14679Espacenet
JP 2026094307 A2026-06-093P14679Espacenet
EP 4705273 A22026-03-11491P14679Espacenet
EP 4650780 A22025-11-192194P14679Espacenet
JP 2025169942 A2025-11-141355P14679Espacenet
EP 4640849 A22025-10-29261P14679Espacenet
EP 4641201 A22025-10-291761P14679Espacenet
JP 2025529142 A2025-09-045138P14679Espacenet
US 12371689 B22025-07-295138P14679Espacenet
JP 2025519096 A2025-06-24261P14679Espacenet

Drugs 3

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ARBUTINCHEMBL232202Tyrosinase inhibitorINHIBITORChEMBL
MEQUINOLCHEMBL544Tyrosinase inhibitorINHIBITORChEMBL
MONOBENZONECHEMBL1388Tyrosinase inhibitorINHIBITORChEMBL

Trials 1

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT00717652ARBUTINPHASE2/PHASE3ClinicalTrials.gov

NIH grants 3260

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA008748Cancer Center Support Grant502,025NIH's project files
P30CA016672Cancer Center Support Grant292,025NIH's project files
R01DK031450Mechanistic Intermediates in Copper Oxygenases and Oxidases292,025NIH's project files
P30CA044579University of Virginia Cancer Center Support Grant272,025NIH's project files
R01AR043369MITF from control of pigmentation to melanoma risk272,025NIH's project files
ZIAEY000476Proteins From Hereditary Eye Diseases: In silico and Experimental Studies232,025NIH's project files
P01CA163222Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment212,025NIH's project files
ZIAHG000215Human Biochemical Genetics202,025NIH's project files
P30CA006927Comprehensive Cancer Center Program at Fox Chase182,025NIH's project files
ZIABC010984Adoptive Cell Transfer Immunotherapy of Cancer182,025NIH's project files

Papers 18387

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42822710PubTator, text miningPubMed
42820474PubTator, text miningPubMed
42819959PubTator, text miningPubMed
42810595PubTator, text miningPubMed
42809220PubTator, text miningPubMed
42805096PubTator, text miningPubMed
42804705PubTator, text miningPubMed
42801767PubTator, text miningPubMed
42800396PubTator, text miningPubMed
42797474PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license